Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy

• DOI: 10.1172/jci.insight.89140
• Publication Date: 2017-01-11T16:00:40Z
• Authors: Tadahiko Yanagita; Yoji Murata; Daisuke Tanaka; Sei-ichiro Motegi; Eri Arai; Edwin Widyanto Da...; Daisuke Hazama; Ken Washio; Yasuyuki Saito; Takenori Kotani; Hiroshi Ohnishi; Per-Arne Oldenborg; Noel Verjan Garcia; Masayuki Miyasaka; Osamu Ishikawa; Yae Kanai; Takahide Komori; Takashi Matozaki
• Keywords: CD47; Cancer Immunotherapy

Tumor cells are thought to evade immune surveillance through interaction with cells. Much recent attention has focused on the modification of responses as a basis for new cancer treatments. SIRPα is an Ig superfamily protein that inhibits phagocytosis in macrophages upon its ligand CD47 expressed surface target Here, we show highly human renal cell carcinoma and melanoma. Furthermore, anti-SIRPα Ab blocks markedly suppressed tumor formation by or melanoma immunocompetent syngeneic mice. This inhibitory effect appeared be mediated dual mechanisms: direct induction Ab-dependent cellular blockade CD47-SIRPα signaling negatively regulates such phagocytosis. The antitumor was greatly attenuated selective depletion not only but also NK CD8+ T In addition, enhances effects Abs against CD20 programmed death 1 (PD-1) mice injected SIRPα-nonexpressing Anti-SIRPα thus warrant further study potential therapy broad range cancers.